Nuveen’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$232M Sell
2,893,244
-480,987
-14% -$39.7M 0.06% 236
2025
Q4
$288M Sell
3,374,231
-1,167,195
-26% -$95.8M 0.08% 203
2025
Q3
$353M Sell
4,541,426
-64,723
-1% -$5.06M 0.09% 179
2025
Q2
$360M Buy
4,606,149
+41,008
+0.9% +$3.06M 0.1% 176
2025
Q1
$331M Buy
4,565,141
+1,395,243
+44% +$99.9M 0.1% 185
2024
Q4
$235M Sell
3,169,898
-216,591
-6% -$15.2M 0.07% 232
2024
Q3
$223M Buy
3,386,489
+332,975
+11% +$24.2M 0.06% 240
2024
Q2
$282M Buy
3,053,514
+474,260
+18% +$42M 0.08% 194
2024
Q1
$246M Sell
2,579,254
-325,197
-11% -$27.3M 0.07% 226
2023
Q4
$221M Sell
2,904,451
-530,398
-15% -$36.9M 0.07% 224
2023
Q3
$238M Sell
3,434,849
-332,839
-9% -$26.7M 0.08% 197
2023
Q2
$355M Sell
3,767,688
-1,227,000
-25% -$107M 0.12% 142
2023
Q1
$413M Sell
4,994,688
-424,788
-8% -$33.4M 0.15% 128
2022
Q4
$404M Sell
5,419,476
-141,672
-3% -$10.9M 0.16% 133
2022
Q3
$460M Sell
5,561,148
-1,048,938
-16% -$101M 0.19% 112
2022
Q2
$629M Buy
6,610,086
+458,309
+7% +$47.4M 0.24% 88
2022
Q1
$686M Buy
6,151,777
+1,750,747
+40% +$196M 0.22% 96
2021
Q4
$570M Buy
4,401,030
+1,533,795
+53% +$179M 0.17% 119
2021
Q3
$325M Sell
2,867,235
-363,021
-11% -$41.4M 0.1% 188
2021
Q2
$335M Sell
3,230,256
-121,771
-4% -$11.5M 0.1% 195
2021
Q1
$280M Sell
3,352,027
-1,256,615
-27% -$106M 0.09% 208
2020
Q4
$420M Buy
4,608,642
+351,774
+8% +$29.2M 0.14% 135
2020
Q3
$340M Sell
4,256,868
-766,973
-15% -$59.8M 0.13% 149
2020
Q2
$347M Sell
5,023,841
-1,286,875
-20% -$91.5M 0.14% 143
2020
Q1
$397M Sell
6,310,716
-2,360,049
-27% -$170M 0.19% 111
2019
Q4
$674M Sell
8,670,765
-2,574,039
-23% -$201M 0.26% 74
2019
Q3
$824M Sell
11,244,804
-609,900
-5% -$42.8M 0.33% 59
2019
Q2
$730M Buy
11,854,704
+11,713,215
+8,279% +$708M 0.29% 68
2019
Q1
$9.02M Sell
141,489
-140,691
-50% -$8.03M 0.05% 431
2018
Q4
$14.4M Sell
282,180
-52,017
-16% -$2.63M 0.09% 337
2018
Q3
$19.4M Buy
334,197
+64,464
+24% +$3.15M 0.1% 315
2018
Q2
$13.1M Buy
269,733
+253,344
+1,546% +$11.8M 0.08% 343
2018
Q1
$762K Sell
16,389
-312
-2% -$13.5K 0.01% 812
2017
Q4
$627K Buy
16,701
+6,570
+65% +$241K ﹤0.01% 860
2017
Q3
$369K Buy
+10,131
New +$386K ﹤0.01% 963
2017
Q1
Sell
-597,096
Closed -$18.6M 1402
2016
Q4
$18.6M Buy
597,096
+61,167
+11% +$1.98M 0.09% 260
2016
Q3
$21.5M Buy
535,929
+18,429
+4% +$694K 0.13% 192
2016
Q2
$17.2M Buy
517,500
+473,934
+1,088% +$16.2M 0.11% 239
2016
Q1
$1.28K Sell
43,566
-1,206
-3% -$33.3K 0.01% 930
2015
Q4
$1.18K Sell
44,772
-4,170
-9% -$108K 0.01% 994
2015
Q3
$1.16K Sell
48,942
-7,140
-13% -$172K 0.01% 1009
2015
Q2
$1.33K Sell
56,082
-228,522
-80% -$5.16M 0.01% 1021
2015
Q1
$6.76M Buy
284,604
+40,866
+17% +$917K 0.04% 457
2014
Q4
$5.17M Buy
243,738
+30,600
+14% +$615K 0.03% 545
2014
Q3
$3.63M Buy
213,138
+144,600
+211% +$2.28M 0.02% 626
2014
Q2
$981K Buy
68,538
+20,622
+43% +$280K 0.01% 1185
2014
Q1
$592K Sell
47,916
-1,560
-3% -$18K ﹤0.01% 1315
2013
Q4
$542K Buy
+49,476
New +$558K ﹤0.01% 1297
2013
Q3
Sell
-53,100
Closed -$595K 1497
2013
Q2
$595K Buy
+53,100
New +$629K ﹤0.01% 1255

Other funds holding EW

Nuveen's EW Position: Q1 2026 in Review

Nuveen reduced its Edwards Lifesciences (EW) stake by 14% in Q1 2026, selling an estimated $39.7M and leaving 2,893,244 shares worth $232M. The position accounts for 0.06% of the portfolio, ranked #236.

Nuveen first reported a position in EW in Q2 2013 and has held it in 49 quarters since. The position peaked at $824M in Q3 2019. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Nuveen held 2,893,244 shares of Edwards Lifesciences worth $232M as of Q1 2026.
  • Nuveen sold 480,987 Edwards Lifesciences shares in Q1 2026, an estimated $39.7M.
  • Edwards Lifesciences made up 0.06% of Nuveen's portfolio in Q1 2026, its #236 holding.
  • Nuveen first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 49 quarters since.
  • Nuveen's Edwards Lifesciences position peaked at $824M in Q3 2019.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.